What psoriasis data from two markets reveals about the gap between access and outcome.

Psoriasis is a global condition. The patient experience around it is not.

Looking at mama health's psoriasis cohort across Germany and the US, the headline number lands in almost exactly the same place. Around 80% of patients in both markets say their treatment isn't working. Two of the most sophisticated healthcare systems in the world, treating the same disease with broadly the same therapeutic classes, are arriving at the same verdict from the people the treatments are designed for. It isn't working.

That's where the similarity ends.

Two markets, two completely different stories

In Germany, conventional therapies post a net patient-reported success rate of -57.9%, and 80.4% of patients describe their treatment as ineffective. Topicals, phototherapy, methotrexate. The bedrock of psoriasis care for decades. Patients in the German cohort describe these treatments in the language of patience running out. They've tried what's been offered, and what's been offered hasn't moved the disease.

Advanced biologics are the only class with a net positive verdict in the German cohort (+15.8%). Patients who are on them report meaningfully better experiences than patients on anything else. And yet biologics remain quietly underutilized in this market. The treatment that patients actually rate as working is not the treatment most patients are on.

The questions German patients bring to mama health every day reflect that reality. They're not asking about insurance coverage or comparing brands. They're asking about the disease itself. The body, the triggers, the connections between what they feel and what they've been diagnosed with. "My back hurts so much in the morning, but it gets better once I start moving. Could this be related to my psoriasis?"

These are the questions of patients who are still trying to understand what is happening to them, and who are operating inside a system that has not yet handed them the treatment that the data says works best.

In the US, the picture inverts. Biologics aren't the exception. They're the headline. Widely prescribed, aggressively marketed, broadly covered. Patients in the US cohort are already deep inside the world of advanced therapy. They know the brand names. They've seen the ads. They've had the conversation with their dermatologist.

And they still report biologics as net unsuccessful (-9.7%), with roughly 78% saying their treatment isn't working overall.

The questions arriving in the US cohort sound different in kind. They are oriented around the system rather than the disease. "My doctor mentioned biologics, but are there any that are actually covered by insurance, or are there clinical studies I could join?" These are not the questions of someone trying to understand their condition. They are the questions of someone trying to navigate it. Trying to find the version of the treatment they can actually access, afford, and stay on.

‍

Same biologic. Opposite verdicts.

If access were the whole story, US numbers should look like Germany's, only better. They look worse. Something is happening between the prescription and the patient that the biologic alone cannot account for.

The German patient is hoping for a treatment they cannot easily get. The US patient has the treatment and is questioning what it's actually delivering. The biologic is constant. The lived experience around it is not.

For commercial teams running multi-market strategy on the same biologic, that is the gap that prescription data, claims data, and market-share dashboards systematically miss. Script volume can rise in a market where patient confidence is collapsing. Coverage can expand in a market where adherence is unravelling. Two markets can look like they're converging on the same therapeutic class while producing two entirely different patient verdicts on it.

The biologic arrives on time. The promise doesn't always follow.

The signal sits ahead of claims data

By the time a switching trend or a reframing of the value proposition shows up in market share or refill data, the patient conversation that explains it is already six to twelve months old. The hope in the German cohort and the disillusionment in the US cohort are leading indicators for what commercial teams will be reading in their dashboards next year.

For a global brand team, the same psoriasis biologic now requires two distinct strategies. In Germany, the constraint is activation. The data says the treatment works. The system isn't yet routing enough patients to it. The commercial question is how to surface the value evidence, the patient-reported outcomes, and the patient education that closes the gap between eligibility and prescription.

In the US, the constraint is something harder. It isn't access, marketing reach, or formulary placement. It's the gap between the experience the patient was led to expect and the experience they're having. That gap won't close with more share-of-voice. It closes with a real understanding of what patients are encountering between the prescription and the outcome, and a willingness to act on what that understanding reveals.

These are not the same problem. Treating them as the same, because the headline number looks the same, is how launches drift off-track in markets that on paper look identical.

The part prescription data was never built to see

Across conditions and across markets, the distance between a prescription and an outcome isn't a data problem. It's a listening problem. It's the part of the patient experience that prescription data was never built to capture, because prescription data was built to record what was prescribed, not how it landed.

What patients say to mama health, before, after, and between every appointment, is the missing layer. It's where the gap between hope and disillusionment becomes visible, where the reasons behind a switching trend appear months before the switching does, and where the difference between two markets that look identical on a dashboard becomes a difference a commercial team can actually act on.

Clinical data wins trials. Patient data wins markets. And the same treatment, in two different markets, with two different patient verdicts, is exactly the kind of finding that only surfaces when patients are heard at scale.

Understanding patients is the foundation of every healthcare decision that follows.

‍